Sector revisions Exact Sciences Corporation
Equities
EXAS
US30063P1057
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.31 USD | -2.53% |
|
-7.88% | -12.24% |
Jan. 23 | Barclays Initiates Exact Sciences at Overweight | MT |
Jan. 13 | Exact Sciences to Seek M&A | CI |
1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
---|---|---|---|---|---|---|---|---|
23 | ||||||||
9 | ||||||||
12 | ||||||||
7 | ||||||||
7 | ||||||||
- | 1 | |||||||
12 | ||||||||
- | - | - | - | |||||
- | - | |||||||
- | - | |||||||
Average | 10 | |||||||
Weighted average by Cap. | 16 |
- Stock Market
- Equities
- EXAS Stock
- Sector Exact Sciences Corporation
- Sector revisions